NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.: Amgen rose $.38 or .7 percent, to $58.69. Biogen Idec rose $.66 or 1.1 percent, to $59.86. Celgene rose $.36 or .6 percent, to $65.38. Gilead Sciences rose $.24 or .5 percent, to $47.66.
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: Amgen rose $.88 or 1.5 percent, to $58.31. Biogen Idec fell $.16 or .3 percent, to $59.20. Celgene rose $.31 or .5 percent, to $65.02. Gilead Sciences rose $.24 or .5 percent, to $47.42.
Biotechnology behemoth Dendreon Corporation (DNDN) was the center of an unusual option play today, with one strategist employing three different puts to bet on a sharp short-term pullback for the stock…( Read More )
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at noon: Amgen rose $.28 or .5 percent, to $57.71. Biogen Idec fell $.52 or .9 percent, to $58.84. Celgene fell $.04 or .1 percent, to $64.68. Gilead Sciences rose $.09 or .2 percent, to $47.27.
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: Amgen rose $.11 or .2 percent, to $57.54. Biogen Idec fell $.89 or 1.5 percent, to $58.48. Celgene rose $.12 or .2 percent, to $64.83. Gilead Sciences rose $.05 or .1 percent, to $47.23.
Background:
Baker’s yeast (Saccharomyces cerevisiae) has been engineered for xylose utilization to enable production of fuel ethanol from lignocellulose raw material. One unresolved challenge is that S. cerevisiae lacks a dedicated transport system for pentose sugars, which means that xylose is transported by non-specific Hxt transporters with comparatively low transport rate and affinity for xylose.
Results:
In this study, we compared three heterologous xylose transporters that have recently been shown to improve xylose uptake under different experimental conditions. The transporters Gxf1, Sut1 and At5g59250 from Candida intermedia, Pichia stipitis and Arabidopsis thaliana, respectively, were expressed in isogenic strains of S. cerevisiae and the transport kinetics and utilization of xylose was evaluated. Expression of the Gxf1 and Sut1 transporters led to significantly increased affinity and transport rates of xylose. In batch cultivation at 4 g/L xylose concentration, improved transport kinetics led to a corresponding increase in xylose utilization, whereas no correlation could be demonstrated at xylose concentrations greater than 15 g/L. The relative contribution of native sugar transporters to the overall xylose transport capacity was also estimated during growth on glucose and xylose.
Conclusions:
Kinetic characterization and aerobic batch cultivation of strains expressing the Gxf1, Sut1 and At5g59250 transporters showed a direct relationship between transport kinetics and xylose growth. The Gxf1 transporter had the highest transport capacity and the highest xylose growth rate, followed by the Sut1 transporter. The range in which transport controlled the growth rate was determined to between 0 and 15 g/L xylose. The role of catabolite repression in regulation of native transporters was also confirmed by the observation that xylose transport by native S. cerevisiae transporters increased significantly during cultivation in xylose and at low glucose concentration.
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: Amgen fell $.30 or .5 percent, to $57.12. Biogen Idec fell $.24 or .4 percent, to $59.49. Celgene rose $.57 or .9 percent, to $63.39. Gilead Sciences fell $.23 or .5 percent, to $47.24.
BALTIMORE, March 17 /PRNewswire-FirstCall/ — Champions Biotechnology, Inc.
Champions Biotechnology, Inc. , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the third  fiscal quarter ended January 31, 2010.  Full details of Company’s financial results are available in the Company’s Form 10-Q at www.championsbiotechnology.com …
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: Amgen rose $.01 or percent, to $57.43. Biogen Idec fell $.37 or .6 percent, to $59.36. Celgene rose $1.89 or 3.0 percent, to $64.71. Gilead Sciences fell $.29 or .6 percent, to $47.18.
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at noon: Amgen fell $.36 or .6 percent, to $57.06. Biogen Idec fell $.31 or .5 percent, to $59.42. Celgene rose $.81 or 1.3 percent, to $63.63. Gilead Sciences fell $.41 or .9 percent, to $47.06.
SALT LAKE CITY, UT–(Marketwire – March 17, 2010) – Green Star Products, Inc. ( PINKSHEETS : GSPI ) and its Consortium announced on March 10, 2010, that it will be auctioning the United States licensing rights to a game changing proprietary algae growth biotechnology on September 9, 2010 (see press release dated March 10, 2010, titled ” Green Star Consortium to Offer Game Changing Biotechnology …
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: Amgen rose $.53 or .9 percent, to $57.42. Biogen Idec rose $.83 or 1.4 percent, to $59.73. Celgene rose $.87 or 1.4 percent, to $62.82. Gilead Sciences fell $.05 or .1 percent, to $47.47.
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at noon: Amgen rose $.44 or .8 percent, to $57.33. Biogen Idec rose $.54 or .9 percent, to $59.44. Celgene rose $.96 or 1.5 percent, to $62.91. Gilead Sciences fell $.06 or .1 percent, to $47.46.
HONOLULU, March 16 /PRNewswire/ — TruTag Technologies, a spinout of Cellular Bioengineering, Inc., was selected as the 2010 North American Pharmaceutical and Biotechnology Innovation of the Year by Frost & Sullivan.
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: Amgen rose $.20 or .4 percent, to $57.09. Biogen Idec rose $.05 or .1 percent, to $58.95. Celgene rose $.64 or 1.0 percent, to $62.59. Gilead Sciences fell $.05 or .1 percent, to $47.47.
Cephalon, Gilead Sciences and Alexion Pharmaceuticals receive top marks from TheStreet’s stock model and sell-side analysts.
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: Amgen fell $.54 or .9 percent, to $56.89. Biogen Idec rose $.14 or .2 percent, to $58.90. Celgene rose $.58 or .9 percent, to $61.95. Gilead Sciences rose $.10 or .2 percent, to $47.52.
Biotechnology company MannKind Corp. said Monday that the Food and Drug Administration has requested more information about the inhaled insulin Afrezza, prompting its shares to plummet.
March 15 (Bloomberg) — MannKind Corp. , the biotechnology company run by billionaire inventor Alfred Mann , failed to win approval from U.S. regulators to market its inhaled insulin drug, Afrezza, for people with diabetes.
A program designed to introduce young women to the fast-growing area of biotechnology has opened its application process to high school girls in the Bay Area.
Syngenta will share information about the use of a new technology that improves efficiency and lowers the cost of genetic data production at the upcoming 52nd Annual Maize Genetic Conference in Riva del Garda, Italy
LEXINGTON, Mass.—-Cubist Pharmaceuticals, Inc. today announced that its President and CEO Michael Bonney will be honored with the second annual Massachusetts Biotechnology Council Innovative Leadership Award.
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at noon: Amgen fell $.69 or 1.2 percent, to $56.74. Biogen Idec fell $.35 or .6 percent, to $58.41. Celgene rose $.11 or .2 percent, to $61.48. Gilead Sciences rose $.05 or .1 percent, to $47.47.
Shares of Boston Scientific fell sharply Monday after the biotechnology company said it has stopped delivery of certain implantable devices for patients with heart disease.